Loading...

Andrew Ko, MD

TitleProfessor
SchoolUCSF School of Medicine
DepartmentMedicine
Address550 16th Street
San Francisco CA 94158
Phone415-353-7286
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Dual Targeting of MEK and EGFR Signaling Pathways in Advanced Pancreatic Cancer
    NIH R21CA149939Sep 19, 2011 - Aug 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Clinical Trials
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko A, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP. Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study. J Gastrointest Oncol. 2016 Dec; 7(6):860-874. PMID: 28078110.
      View in: PubMed
    2. Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials. Pancreas. 2016 Nov; 45(10):1394-1400. PMID: 27171514.
      View in: PubMed
    3. Ko AH. Striving to Move Beyond Chemotherapy in Advanced Pancreatic Cancer. J Oncol Pract. 2016 Sep; 12(9):808-10. PMID: 27621334.
      View in: PubMed
    4. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847. PMID: 27569043.
      View in: PubMed
    5. Kim SS, Nakakura EK, Wang ZJ, Kim GE, Corvera CU, Harris HW, Kirkwood KS, Hirose R, Tempero MA, Ko AH. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol. 2016 Oct; 114(5):587-596. PMID: 27444658.
      View in: PubMed
    6. Williams JR, Tenforde MW, Chan JD, Ko A, Graham SM. Safety and clinical response of intraventricular caspofungin for Scedosporium apiospermum complex central nervous system infection. Med Mycol Case Rep. 2016 Sep; 13:1-4. PMID: 27656356; PMCID: PMC5021765.
    7. Wang VE, Grandis JR, Ko AH. New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. Clin Cancer Res. 2016 Sep 1; 22(17):4283-90. PMID: 27370606.
      View in: PubMed
    8. Ko AH. Raising the bar for the adjuvant treatment of pancreatic cancer. Lancet. 2016 Jul 16; 388(10041):214-5. PMID: 27265348.
      View in: PubMed
    9. Balaban EP, Mangu PB, Khorana AA, Shah MA, Mukherjee S, Crane CH, Javle MM, Eads JR, Allen P, Ko AH, Engebretson A, Herman JM, Strickler JH, Benson AB, Urba S, Yee NS. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 Aug 1; 34(22):2654-68. PMID: 27247216.
      View in: PubMed
    10. Gridelli C, Ko A, O'Brien M, Ong TJ, Socinski MA, Postmus PE. 216PD: nab-Paclitaxel + carboplatin (nab-P/C) in advanced non-small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology. J Thorac Oncol. 2016 Apr; 11(4 Suppl):S154-5. PMID: 27198356.
      View in: PubMed
    11. Ko A, LoConte N, Tempero MA, Walker EJ, Kate Kelley R, Lewis S, Chang WC, Kantoff E, Vannier MW, Catenacci DV, Venook AP, Kindler HL. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Apr; 45(3):370-5. PMID: 26390428.
      View in: PubMed
    12. Ko AH. Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. Int J Nanomedicine. 2016; 11:1225-35. PMID: 27099488.
      View in: PubMed
    13. Coveler AL, Ko AH, Catenacci DV, Von Hoff D, Becerra C, Whiting NC, Yang J, Wolpin B. A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers. Invest New Drugs. 2016 Jun; 34(3):319-28. PMID: 26994014.
      View in: PubMed
    14. Ko AH. Pancreatic Cancer and the Possibility of Long-term Survival: A Glimmer of Hope? JAMA Oncol. 2016 Mar 1; 2(3):380-1. PMID: 26658827.
      View in: PubMed
    15. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko A, Kelley RK, Korn WM, Esserman LJ, Van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. PMID: 26875185.
      View in: PubMed
    16. Chiorean EG, Von Hoff DD, Reni M, Arena FP, Infante JR, Bathini VG, Wood TE, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Goldstein D, McGovern D, Lu B, Ko A. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. Ann Oncol. 2016 Apr; 27(4):654-60. PMID: 26802160.
      View in: PubMed
    17. Carnevale J, Ko AH. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncol. 2016 Feb; 12(4):453-64. PMID: 26685802.
      View in: PubMed
    18. Ko A, Bekaii-Saab T, van Ziffle J, Mirzoeva OK, Joseph N, Talasaz A, Kuhn P, Tempero MA, Collisson E, Kelley RK, Venook A, Dito E, Ong A, Ziyeh S, Courtin R, Linetskaya R, Tahiri S, Korn WM. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016 Jan 1; 22(1):61-8. PMID: 26251290.
      View in: PubMed
    19. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. PMID: 26109333; PMCID: PMC4592417.
    20. Pollom EL, Koong AC, Ko AH. Treatment Approaches to Locally Advanced Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015 Aug; 29(4):741-59. PMID: 26226908.
      View in: PubMed
    21. Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015 Jun 1; 33(16):1779-86. PMID: 25918299.
      View in: PubMed
    22. Ahn DH, Ko AH, Meropol NJ, Bekaii-Saab TS. Making sense of current and emerging therapies in pancreatic cancer: balancing benefit and value. Am Soc Clin Oncol Educ Book. 2015; e222-7. PMID: 25993177.
      View in: PubMed
    23. Walker EJ, Simko JP, Nakakura EK, Ko AH. A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol. 2014 Dec; 5(6):E88-95. PMID: 25436138; PMCID: PMC4226816.
    24. Tempero MA, Malafa MP, Behrman SW, Benson AB, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2014 Aug; 12(8):1083-93. PMID: 25099441.
      View in: PubMed
    25. Walker EJ, Simko JP, Ko AH. Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor. Anticancer Res. 2014 Jul; 34(7):3629-34. PMID: 24982379.
      View in: PubMed
    26. Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP. 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. J Gastrointest Cancer. 2014 Jun; 45(2):168-80. PMID: 24448917.
      View in: PubMed
    27. Van Loon K, Espinoza AM, Fogelman DR, Wolff RA, Javle MM, Iyer RV, Picozzi VJ, Martin LK, Bekaii-Saab T, Tempero MA, Foster NR, Kim GP, Ko AH. Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab. Pancreas. 2014 Apr; 43(3):343-9. PMID: 24622062; PMCID: PMC3955845.
    28. Pant S, Martin LK, Geyer S, Wei L, Van Loon K, Sommovilla N, Zalupski M, Iyer R, Fogelman D, Ko AH, Bekaii-Saab T. Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab. Cancer. 2014 Jun 15; 120(12):1780-6. PMID: 24633933; PMCID: PMC4265390.
    29. Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? World J Gastroenterol. 2014 Mar 7; 20(9):2224-36. PMID: 24605022; PMCID: PMC3942828.
    30. Cinar P, Ko AH. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2014 Feb; 12(2):167-72. PMID: 24586078.
      View in: PubMed
    31. Ko AH. Expanding options for pancreatic cancer... so where do we go from here? Oncology (Williston Park). 2014 Jan; 28(1):5. PMID: 24683713.
      View in: PubMed
    32. Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct 1; 109(7):1725-34. PMID: 24022191; PMCID: PMC3790192.
    33. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mol Cancer Ther. 2013 Oct; 12(10):2213-25. PMID: 23918833; PMCID: PMC3800201.
    34. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20; 109(4):920-5. PMID: 23880820; PMCID: PMC3749576.
    35. Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013 Jul; 24(7):1900-7. PMID: 23519998; PMCID: PMC3690907.
    36. Ko A, Su DK, Born D, DeSantis A, Alan Failor R, Ferreira M. Two patients with primary sellar leiomyomas, a rare entity. J Clin Neurosci. 2013 Jun; 20(6):897-901. PMID: 23219820.
      View in: PubMed
    37. Ko AH, Cella D. Achieving the best of both worlds. J Clin Oncol. 2013 Jan 1; 31(1):3-4. PMID: 23213099.
      View in: PubMed
    38. Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA. Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas. Am J Clin Oncol. 2012 Oct; 35(5):411-7. PMID: 21552099.
      View in: PubMed
    39. Ko AH, Truong TG, Kantoff E, Jones KA, Dito E, Ong A, Tempero MA. A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2012 Dec; 70(6):875-81. PMID: 23053263.
      View in: PubMed
    40. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB, Casper ES, Cohen SJ, Czito B, Ellenhorn JD, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Ma WW, Malafa MP, Merchant NB, Mulvihill SJ, Muscarella P, Nakakura EK, Obando J, Pitman MB, Sasson AR, Tally A, Thayer SP, Whiting S, Wolff RA, Wolpin BM, Freedman-Cass DA, Shead DA. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012 Jun 1; 10(6):703-13. PMID: 22679115; PMCID: PMC3807091.
    41. Cho EH, Wendel M, Luttgen M, Yoshioka C, Marrinucci D, Lazar D, Schram E, Nieva J, Bazhenova L, Morgan A, Ko AH, Korn WM, Kolatkar A, Bethel K, Kuhn P. Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol. 2012 Feb; 9(1):016001. PMID: 22306705; PMCID: PMC3387999.
    42. Marrinucci D, Bethel K, Kolatkar A, Luttgen MS, Malchiodi M, Baehring F, Voigt K, Lazar D, Nieva J, Bazhenova L, Ko AH, Korn WM, Schram E, Coward M, Yang X, Metzner T, Lamy R, Honnatti M, Yoshioka C, Kunken J, Petrova Y, Sok D, Nelson D, Kuhn P. Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol. 2012 Feb; 9(1):016003. PMID: 22306768; PMCID: PMC3387996.
    43. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 1; 30(1):88-109. PMID: 22147736.
      View in: PubMed
    44. Ko AH. FOLFIRINOX: a small step or a great leap forward? J Clin Oncol. 2011 Oct 1; 29(28):3727-9. PMID: 21900100.
      View in: PubMed
    45. Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1597-606. PMID: 21629990.
      View in: PubMed
    46. Ko AH, Tempero MA, Shan Y, Su W, Lin Y, Dito E, Ong A, Wang Y, Yeh G, Chen L. A multinational phase II study of PEP02 (liposome irinotecan) for patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4069. PMID: 28020493.
      View in: PubMed
    47. Alsina M, Ko AH, Garcia De Paredes M, Rivera F, Schwartzberg LS, Fattaey A, Kunkel LA, Tabernero J, Ajani JA. Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):4122. PMID: 28021229.
      View in: PubMed
    48. Espinoza AM, Ko AH, Ostroff JW, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Tempero MA. Biliary stent complications in clinical trials for advanced pancreatic cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e14665. PMID: 28021416.
      View in: PubMed
    49. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011 Apr; 17(4):500-3. PMID: 21460848; PMCID: PMC3755490.
    50. Kraus VB, Burnett B, Coindreau J, Cottrell S, Eyre D, Gendreau M, Gardiner J, Garnero P, Hardin J, Henrotin Y, HeinegÄrd D, Ko A, Lohmander LS, Matthews G, Menetski J, Moskowitz R, Persiani S, Poole AR, Rousseau JC, Todman M. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthritis Cartilage. 2011 May; 19(5):515-42. PMID: 21396468; PMCID: PMC3568396.
    51. Ko AH, Tempero MA, Shan Y, Su W, Lin Y, Dito E, Ong A, Yeh G, Chen L. A multinational phase II study of liposome irinotecan (PEP02) for patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2011 Feb; 29(4_suppl):237. PMID: 27985453.
      View in: PubMed
    52. Kelley RK, Nimeiri HS, Vergo MT, Chia K, Mulcahy MF, Bergsland EK, Ko AH, Munster PN, Benson AB, Venook AP. Phase I trial of temsirolimus (TEM) plus sorafenib (SOR) in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2011 Feb; 29(4_suppl):296. PMID: 27985689.
      View in: PubMed
    53. Gordan JD, Chay WY, Kelley RK, Ko AH, Choo SP, Venook AP. "And what other medications are you taking?". J Clin Oncol. 2011 Apr 10; 29(11):e288-91. PMID: 21245436.
      View in: PubMed
    54. Ko AH, Crane CH. Radiation therapy in operable and locally advanced pancreatic cancer. J Natl Compr Canc Netw. 2010 Sep; 8(9):1022-31. PMID: 20876542.
      View in: PubMed
    55. Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2010 Nov; 66(6):1051-7. PMID: 20130876.
      View in: PubMed
    56. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 1; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
    57. Ko AH, Tempero MA. Personalized medicine for pancreatic cancer: a step in the right direction. Gastroenterology. 2009 Jan; 136(1):43-5. PMID: 19041649.
      View in: PubMed
    58. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008 Oct; 37(3):269-74. PMID: 18815548.
      View in: PubMed
    59. Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs. 2008 Oct; 26(5):463-71. PMID: 18379729.
      View in: PubMed
    60. Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics. 2008 Mar; 2(1):83-95. PMID: 19707431; PMCID: PMC2727779.
    61. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer Invest. 2008 Feb; 26(1):47-52. PMID: 18181045.
      View in: PubMed
    62. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M, Schillinger B, Liu W, Lu Y, Mitsky P, Schilling M, Bercovici N, Loudovaris M, Guillermo R, Lee SM, Bender J, Mills B, Fong L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother. 2007 Oct; 30(7):762-72. PMID: 17893568.
      View in: PubMed
    63. Ko AH. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol. 2007 Aug; 34(4):354-64. PMID: 17674964.
      View in: PubMed
    64. Ko AH, Wang F, Holly EA. Pancreatic cancer and medical history in a population-based case-control study in the San Francisco Bay Area, California. Cancer Causes Control. 2007 Oct; 18(8):809-19. PMID: 17632765.
      View in: PubMed
    65. Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA. A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2007 Jul 1; 68(3):809-16. PMID: 17363191.
      View in: PubMed
    66. Ko AH, Dito E, Schillinger B, Hajnal R, Venook AP, Bergsland EK, Allen J, Rajpal S, Tempero MA. A phase II study of gemcitabine (GEM) given at fixed-dose rate (FDR) infusion, low-dose cisplatin (CDDP), and bevacizumab in metastatic pancreatic cancer (PanCa). J Clin Oncol. 2006 Jun 20; 24(18_suppl):4041. PMID: 27953645.
      View in: PubMed
    67. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 Jan 20; 24(3):379-85. PMID: 16344320.
      View in: PubMed
    68. Ko AH, Tempero MA. Systemic therapy for pancreatic cancer. Semin Radiat Oncol. 2005 Oct; 15(4):245-53. PMID: 16183478.
      View in: PubMed
    69. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw. 2005 Sep; 3(5):627-36. PMID: 16194454.
      View in: PubMed
    70. Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer. 2005 Jul 25; 93(2):195-9. PMID: 15999098; PMCID: PMC2361548.
    71. Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Allen J, Tempero MA. A phase II study of fixed-dose rate (FDR) gemcitabine plus cisplatin for metastatic pancreatic adenocarcinoma (PanCa). J Clin Oncol. 2004 Jul 15; 22(14_suppl):4107. PMID: 28014499.
      View in: PubMed
    72. Ko AH, Bergsland EK, Lee GA. Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature. Dig Dis Sci. 2003 Jan; 48(1):192-6. PMID: 12645810.
      View in: PubMed
    73. Ko AH, Yuen AR. Clinical outcomes associated with very late relapses in diffuse large cell lymphoma. Leuk Lymphoma. 2002 Sep; 43(9):1789-93. PMID: 12685833.
      View in: PubMed
    74. Ko AH, Tempero MA. Current and future strategies for combined-modality therapy in pancreatic cancer. Curr Oncol Rep. 2002 May; 4(3):202-12. PMID: 11937010.
      View in: PubMed
    75. Harmon EB, Ko AH, Kim SK. Hedgehog signaling in gastrointestinal development and disease. Curr Mol Med. 2002 Feb; 2(1):67-82. PMID: 11898849.
      View in: PubMed
    76. Lee SR, Ramos SM, Ko A, Masiello D, Swanson KD, Lu ML, Balk SP. AR and ER interaction with a p21-activated kinase (PAK6). Mol Endocrinol. 2002 Jan; 16(1):85-99. PMID: 11773441.
      View in: PubMed
    77. Patterson S, Ko A, O'Connell TX. Radiation after mastectomy in high-risk patients: is it necessary? Am Surg. 2001 Dec; 67(12):1209-12. PMID: 11768832.
      View in: PubMed
    78. Chen Z, Ko A, Yang J, Jordan VC. Methylation of CpG island is not a ubiquitous mechanism for the loss of oestrogen receptor in breast cancer cells. Br J Cancer. 1998; 77(2):181-5. PMID: 9460986; PMCID: PMC2151219.
    79. Gallant JE, Ko AH. Cavitary pulmonary lesions in patients infected with human immunodeficiency virus. Clin Infect Dis. 1996 Apr; 22(4):671-82. PMID: 8729207.
      View in: PubMed
    80. Ko AH, Thomas DL, Gallant JE. Non-Hodgkin's lymphoma and Kaposi's sarcoma causing cavitary lung lesions in a patient with AIDS: an HIV-associated collision tumor. AIDS. 1995 Oct; 9(10):1195-7. PMID: 8519459.
      View in: PubMed
    81. Ko AH. Repression, denial, backlash: sexually transmitted diseases in the People's Republic of China. Pharos Alpha Omega Alpha Honor Med Soc. 1994; 57(2):11-5. PMID: 8022868.
      View in: PubMed
    Andrew's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP